Arcturus Therapeutics (ARCT) Tops Q3 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARCT Hot Sheet
Join SI Premium – FREE
Arcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($0.26), $0.31 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $41.67 million versus the consensus estimate of $53.46 million.
For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phibro Animal Health (PAHC) Tops Q1 EPS by 2c; Offers Guidance
- Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 EPS by 12c; Offers Guidance
- Barrick Gold (GOLD) Misses Q3 EPS by 88c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
